These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35294453)

  • 1. Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).
    Dworatzyk K; Jansen T; Schmidt TT
    PLoS One; 2022; 17(3):e0264927. PubMed ID: 35294453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).
    Nour MM; Evans L; Nutt D; Carhart-Harris RL
    Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
    Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences.
    Orłowski P; Ruban A; Szczypiński J; Hobot J; Bielecki M; Bola M
    J Psychopharmacol; 2022 Aug; 36(8):987-1000. PubMed ID: 35475373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
    Kuc J; Kettner H; Rosas F; Erritzoe D; Haijen E; Kaelen M; Nutt D; Carhart-Harris RL
    Psychopharmacology (Berl); 2022 May; 239(5):1425-1440. PubMed ID: 34734314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation and latent structure of the Brazilian version of the Ego Dissolution Inventory (EDI-BR): an exploratory study.
    Bienemann B; Longo MSC; Ridolfi M; Multedo M; Cruz LVM; Schenberg E; Tófoli LF; Mograbi DC
    Trends Psychiatry Psychother; 2024; 46():e20220491. PubMed ID: 36283045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the Japanese version of the Ego-Dissolution Inventory (EDI).
    Kusudo K; Tani H; Yonezawa K; Nakajima S; Nour MM; Carhart-Harris R; Uchida H
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):292-297. PubMed ID: 38318991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
    Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
    Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
    J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.
    Lebedev AV; Lövdén M; Rosenthal G; Feilding A; Nutt DJ; Carhart-Harris RL
    Hum Brain Mapp; 2015 Aug; 36(8):3137-53. PubMed ID: 26010878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel ego dissolution scale: A construct validation study.
    Sleight FG; Lynn SJ; Mattson RE; McDonald CW
    Conscious Cogn; 2023 Mar; 109():103474. PubMed ID: 36764162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenomenology, Structure, and Dynamic of Psychedelic States.
    Preller KH; Vollenweider FX
    Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.
    Mason NL; Kuypers KPC; Müller F; Reckweg J; Tse DHY; Toennes SW; Hutten NRPW; Jansen JFA; Stiers P; Feilding A; Ramaekers JG
    Neuropsychopharmacology; 2020 Nov; 45(12):2003-2011. PubMed ID: 32446245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences.
    Davis AK; Timmermann C; Ortiz Bernal AM; Lancelotta R; Nayak S; Sepeda ND; Nikolaidis A; Griffiths RR
    J Psychoactive Drugs; 2023 Jul; ():1-11. PubMed ID: 37449499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-response relationships of psilocybin-induced subjective experiences in humans.
    Hirschfeld T; Schmidt TT
    J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.